Death-associated protein kinase 1 phosphorylates MDM2 and inhibits its protein stability and function

Area of Science:

• Oncology
• Molecular Biology
• Biochemistry

Background:

• Breast cancer is a leading cause of female mortality, often driven by recurrence, drug resistance, and metastasis.
• The mouse double minute 2 (MDM2) oncogene is frequently overexpressed in breast cancer, but its regulation is not fully understood.

Purpose of the Study:

• To identify novel regulators of MDM2 in breast cancer.
• To elucidate the functional role of DAPK1 in breast cancer progression and its relationship with MDM2.

Main Methods:

• Unbiased peptide library screening to identify MDM2-interacting proteins.
• In vitro kinase assays and Western blotting to assess MDM2 phosphorylation and degradation.
• Cell-based assays (colony formation, doxorubicin-induced cell death) and xenograft tumorigenesis models.
• Analysis of DAPK1 and MDM2 expression in human breast cancer tissues.

Main Results:

• Death-associated protein kinase 1 (DAPK1) was identified as a novel MDM2 regulator, directly binding and phosphorylating MDM2 at Thr419.
• DAPK1-mediated MDM2 phosphorylation enhances MDM2 protein degradation via the ubiquitin-proteasome pathway, leading to increased p53 levels.
• DAPK1 overexpression suppressed breast cancer cell proliferation and enhanced doxorubicin sensitivity, while DAPK1 knockdown had opposite effects.
• DAPK1 overexpression reduced tumor formation in vivo, and its kinase activity was crucial for this antitumorigenic effect.
• A negative correlation was observed between DAPK1 and MDM2 expression levels in human breast cancer tissues.

Conclusions:

• DAPK1 acts as a tumor suppressor in breast cancer by phosphorylating and promoting the degradation of the MDM2 oncogene.
• This DAPK1-mediated pathway, involving MDM2 degradation and p53 upregulation, represents a potential therapeutic target for breast cancer treatment.